You are here

ShareSpot: rapid treatment

  • FDA Approves 2-Drug Combination of Dolutegravir + Lamivudine

    Susa Coffey's picture

    In April 2019, the U.S. Food and Drug Administration approved a combination pill comprising the integrase inhibitor dolutegravir (DTG), 50 mg, and the NRTI lamivudine (3TC), 300 mg, for use as a complete ARV regimen for initial HIV treatment of patients. The approval specifies that DTG/3TC is...